Board approves share allotment, director re-appointment, Singapore subsidiary

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+10.2%1-day move

₹317.50

prior close

₹323.95

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.2+0.0+0.1+1.6+10.2+12.3+13.1+9.9+12.5+2.2————

Up moveDown movePending

AI summary

Board approved three items: (1) Allotted 1.85 crore equity shares to 17 non-promoter investors at Rs 134 per share via warrant conversion, raising Rs 248.84 crore. Paid-up capital rose to Rs 28.26 crore (28.26 crore shares). (2) Re-appointed Dr. Vajja Sambasiva Rao as Independent Director for a second 5-year term from Jan 21, 2027. (3) Incorporated wholly owned subsidiary Suven Neurosciences Pte. Ltd. in Singapore for clinical-stage biopharma in neurological disorders, with USD 100 million planned investment.

Likely market impact

Capital raised via warrant conversion strengthens balance sheet. Singapore WOS signals global expansion in neurology. Director continuity maintained.